US 12,391,672 B2
Solid forms comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same
Antonio C. Ferretti, Summit, NJ (US); Lianfeng Huang, Basking Ridge, NJ (US); Udaykumar Jain, Plainsboro, NJ (US); Hon-Wah Man, Princeton, NJ (US); Paula A. Tavares-Greco, Parsippany, NJ (US); and Wenju Wu, Warren, NJ (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Filed by Celgene Corporation, Summit, NJ (US)
Filed on May 27, 2022, as Appl. No. 17/827,491.
Application 17/827,491 is a continuation of application No. 16/737,739, filed on Jan. 8, 2020, granted, now 11,370,777.
Claims priority of provisional application 62/790,342, filed on Jan. 9, 2019.
Prior Publication US 2022/0289713 A1, Sep. 15, 2022
Int. Cl. C07D 401/14 (2006.01)
CPC C07D 401/14 (2013.01) [C07B 2200/13 (2013.01)] 7 Claims
 
1. A solid form of a free base of Compound 1:

OG Complex Work Unit Chemistry
characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at approximately 14.6, 18.2, and 18.3° 2θ.